Method for detecting genotoxic impurities 2-mercaptobenzothiazole and dibenzothiazyl disulfide
The detection challenges of dibenzothiazole disulfide and 2-mercaptobenzothiazole were solved by high-performance liquid chromatography and glutathione derivatization, achieving high sensitivity and specificity in detection, which is suitable for process control and mass spectrometry analysis of antibiotic drugs.
Patent Information
- Application Number
- CN202411238512.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-22
AI Technical Summary
Existing technologies are insufficient for the simultaneous and efficient detection and separation of unstable dibenzothiazole disulfide and 2-mercaptobenzothiazole, and also lack sufficient sensitivity and specificity.
High performance liquid chromatography (HPLC) was employed, using glutathione as a reducing agent and stabilizer. Derivatization HPLC was used to detect 2-mercaptobenzothiazole and dibenzothiazole disulfide in antibiotics. Appropriate mobile phase and chromatographic conditions were selected, including gradient elution, detection wavelength, column, and temperature.
It achieves high sensitivity and specificity of detection, good separation, simple operation, and is suitable for process control and mass spectrometry analysis. It is compatible with more detectors, has mild reaction conditions, and high accuracy.
Smart Images

Figure CN119000944A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of traditional Chinese medicine analysis, and in particular to a method for detecting genotoxic impurities 2-mercaptobenzothiazole and dibenzothiazole disulfide. Background Art
[0002] Dibenzothiazyl disulfide (Formula II), English name: Accelerator (DM), molecular formula: C 14 H8N2S4, molecular weight: 332.47. It is a vulcanization accelerator DM and an important intermediate for the synthesis of cephalosporin antibiotics. In the process of preparing cephalosporin antibiotics using the AE active ester method, a by-product 2-mercaptobenzothiazole is produced.
[0003] 2-Mercaptobenzothiazole, English name: 2-Mercaptobenzothiazole, molecular formula: C7H5NS2, molecular weight: 167.25. It is the promoter M and a byproduct of the synthesis of cephalosporin antibiotics. On October 27, 2017, the World Health Organization's International Agency for Research on Cancer published a preliminary list of carcinogens for reference, and 2-mercaptobenzothiazole is on the list of Class 2A carcinogens.
[0004] Literature shows that: dibenzothiazole disulfide is unstable and can be reduced to 2-mercaptobenzothiazole; 2-mercaptobenzothiazole can also be oxidized and freely converted to its oxidized form of dibenzothiazole disulfide in solution and in vivo; the two have large polarity differences and large retention differences in liquid chromatography columns; dibenzothiazole disulfide has a maximum absorption at 274nm, while 2-mercaptobenzothiazole has a weaker absorption; 2-mercaptobenzothiazole has a maximum absorption at 322nm, while dibenzothiazole disulfide has a weaker absorption; therefore, it is difficult to achieve the required sensitivity of the two impurities using a set of liquid phase methods, and a combined control strategy can effectively solve this problem. The key to solving the problem is to find a suitable oxidant or reductant.
[0005] Glutathione has an antioxidant effect and is a good reducing agent. Under physiological conditions, there are two forms of reduced glutathione (GSSG) and oxidized glutathione (GSH), but the original glutathione accounts for the majority and is the source of the antioxidant effect. Reduced glutathione is easily oxidized to oxidized glutathione when it encounters an oxidant, and as a reducing agent, it can break disulfide bonds, generate oxidized glutathione itself, and reduce disulfide bonds to sulfhydryls (-SH). It can participate in the reaction as a reducing agent and can also act as a stabilizer to sacrifice itself to protect the reduction product from oxidation.
[0006] According to the difference in properties between dibenzothiazole disulfide and 2-mercaptobenzothiazole, reduced glutathione can be selected as a reducing agent and stabilizer for converting dibenzothiazole disulfide into 2-mercaptobenzothiazole, and the two impurities can be quantified uniformly with stable 2-mercaptobenzothiazole using high performance liquid chromatography, thereby achieving the purpose of combined control. Summary of the invention
[0007] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a highly sensitive, specific, economical and efficient derivatization liquid chromatography method for detecting the content of unstable toxic impurities 2-mercaptobenzothiazole and dibenzothiazole disulfide in antibiotic drugs.
[0008] The objective of the present invention is achieved through the following technical solutions:
[0009] A method for detecting 2-mercaptobenzothiazole and dibenzothiazole disulfide in cephalosporin drugs, wherein the detection method adopts high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography include: using 0.05-0.2% formic acid aqueous solution as mobile phase A, using acetonitrile as mobile phase B, and the gradient elution conditions are:
[0010] 0 min, mobile phase A: 65-75%, mobile phase B: 25-35%;
[0011] 20 min, mobile phase A: 65-75%, mobile phase B: 25-35%;
[0012] Preferably, in the chromatographic conditions, the detection wavelength is 319 nm, and the chromatographic column uses octadecylsilane bonded silica gel as a filler.
[0013] Preferably, the chromatographic column is YMC-PackC18, and the size of the chromatographic column is 4.6x150mm, 3μm.
[0014] Preferably, in the chromatographic conditions, the flow rate of the mobile phase is 0.6-1.0 mL / min, and the column temperature is 35-45°C.
[0015] Preferably, the method further comprises:
[0016] (1) Preparation of the test sample derivatization solution: dissolving the antibiotic sample in glutathione solution and subjecting it to derivatization reaction;
[0017] (2) Preparation of reference substance derivatization solution: The reference substance is dissolved in dimethyl sulfoxide to prepare a 0.5 mg / mL solution. The solution is diluted with solvent to prepare a stock solution. The stock solution is diluted with glutathione solution and the derivatization reaction is performed.
[0018] Preferably, the temperature of the derivatization reaction in steps (1) and (2) is 40-50°C.
[0019] Preferably, the derivatization reaction time in steps (1) and (2) is 0.5-6 h.
[0020] Preferably, the preparation of the glutathione solution in steps (1) and (2) comprises dissolving glutathione in water and diluting it with ethanol.
[0021] Preferably, the reference substance in step (2) is 2-mercaptobenzothiazole and dibenzothiazole disulfide.
[0022] Preferably, the solvent in step (2) is a 20-40% methanol solution.
[0023] Beneficial effects of the present invention:
[0024] (1) The present invention adopts a derivative liquid chromatography method to detect the content of the base toxic impurities 2-mercaptobenzothiazole and dibenzothiazole disulfide in antibiotic drugs. The method has good specificity, high sensitivity, good separation, good solution stability, simple operation, mild reaction conditions, high accuracy, and is suitable for process control and release detection, and can also be used for mass spectrometry analysis.
[0025] (2) The mobile phase preparation in the chromatographic conditions of the present invention is simpler and easier to operate, and can be applied to more detectors; the present invention further found that the amount of glutathione and the derivatization reaction conditions have a greater impact on the detection effect, and the effect is significantly better under the derivatization reaction conditions of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a comparison chart of the specificity and sensitivity solutions of Example 1;
[0027] Figure 2 It is a partial enlarged diagram of the specificity and sensitivity solution comparison diagram of Example 1;
[0028] Figure 3 This is the chromatogram of the derivatized solution of the dibenzothiazyl disulfide reference substance of Example 1;
[0029] Figure 4 This is the chromatogram of the test solution in Example 1;
[0030] Figure 5 This is a partial enlarged view of the chromatogram of the test solution in Example 1;
[0031] Figure 6 This is a comparison diagram of the suitability of solutions for different chromatographic column systems in Example 2;
[0032] Figure 7 This is a partial enlarged view of the comparison of solutions for suitability of different chromatographic column systems in Example 2;
[0033] Figure 8This is a comparison diagram of system suitability solutions of different mobile phase initial ratios in Example 3;
[0034] Fig. 9 This is a comparison diagram of the system applicability solutions at different flow rates in Example 4;
[0035] Fig.10 This is a partial enlarged view of the comparison of solutions with different flow rates for system applicability in Example 4;
[0036] Fig.11 This is a comparison diagram of the solutions for different column temperature systems in Example 5;
[0037] Fig.12 This is a partial enlarged view of the comparison of solutions for different column temperature system applicability in Example 5;
[0038] Fig.13 This is a comparison diagram of the system applicability solutions of different derivatization temperatures in Example 6;
[0039] Fig.14 This is a partial enlarged view of the comparison of the system applicability solutions of different derivatization temperatures in Example 6;
[0040] Fig.15 This is a comparison diagram of the system applicability solutions of different derivatization times in Example 7;
[0041] Fig.16 This is the spectrum of dibenzothiazyl disulfide of Comparative Example 1;
[0042] Fig.17 This is the spectrum of 2-mercaptobenzothiazole in Comparative Example 1;
[0043] Fig.18 This is the chromatogram of the dibenzothiazole disulfide reference solution of Comparative Example 1;
[0044] Fig.19 This is a partial enlarged view of the chromatogram of the dibenzothiazole disulfide reference substance solution in Comparative Example 1;
[0045] Fig. 20 This is the chromatogram of the 2-mercaptobenzothiazole reference substance solution in Comparative Example 1;
[0046] Fig.21 It is a partial enlarged view of the chromatogram of the 2-mercaptobenzothiazole reference substance solution in Comparative Example 1;
[0047] Fig. 22 This is a comparison chart of the specificity of Comparative Example 1;
[0048] Fig.23 This is a partial enlarged view of the specificity comparison of Comparative Example 1;
[0049] Fig.24 This is a comparison diagram of the specific solution of Comparative Example 2;
[0050] Fig.25 This is a partial enlarged view of the specific solution comparison of Comparative Example 2;
[0051] Fig.26 This is a comparison chart of the specificity of Comparative Example 3;
[0052] Fig. 27 This is a partial enlarged view of the specificity comparison diagram of Comparative Example 3.
[0053] The unclear parts in the above pictures do not affect the understanding of the technical solutions and effects of the present invention by those skilled in the art. DETAILED DESCRIPTION
[0054] The present invention is further described below in conjunction with specific implementation methods.
[0055] The test instrument, chromatographic column, mobile phase, injection volume, detection wavelength, flow rate, column temperature, and elution gradient are shown in Table 1:
[0056] Table 1
[0057]
[0058] The solution preparation is as shown in Table 2:
[0059] Table 2
[0060]
[0061] Example 1
[0062] Take the above solution and inject it into the liquid chromatograph according to the above chromatographic conditions, and record the chromatogram. Figure 1-5 .
[0063] Conclusion: The blank derivatization solution and the test sample derivatization solution do not interfere with the detection of 2-mercaptobenzothiazole and dibenzothiazole disulfide; the separation degree of the derivatization peak of dibenzothiazole disulfide in the system suitability solution is 15.30 and the spike recovery rate is 101.0%; the signal-to-noise ratio of 2-mercaptobenzothiazole in the sensitivity solution is 38.8; the retention time of 2-mercaptobenzothiazole in the dibenzothiazole disulfide reference substance derivatization solution and the 2-mercaptobenzothiazole reference substance derivatization solution is consistent; the method has good specificity and high sensitivity. In addition, the retention time of the main peak of the test solution and 2-mercaptobenzothiazole is within 20 minutes, which can shorten the analysis time according to the detection requirements, and achieve the purpose of rapid detection of 2-mercaptobenzothiazole and dibenzothiazole disulfide under the same method.
[0064] Example 2
[0065] Other conditions were the same as in Example 1, except that the chromatographic columns were replaced with GL Sciences Inertsil ODS-3 4.0x150mm 3μm, Waters Atlantis T3 4.6x150mm 3μm, Thermo Scientific ODS HYpersil 125x4.6mm 3μm, and Agilent poroshell EC-C18 4.6x150mm 2.7μm.
[0066] The results are as follows Figure 6-7 As shown in the figure, under different chromatographic column conditions, the retention time of 2-mercaptobenzothiazole in the system suitability derivatization solution was moderate, and the separation, recovery rate and sensitivity all met the detection requirements, and the method had good durability.
[0067] Example 3
[0068] The other conditions were the same as in Example 1, and the initial ratios of mobile phase A:acetonitrile were 60:40, 70:30, and 80:20, respectively. Figure 8 As shown, with the change of the initial ratio of mobile phase A: acetonitrile, the retention time of 2-mercaptobenzothiazole in the system suitability derivatization solution is moderate, and the separation, recovery rate and sensitivity all meet the detection requirements. The initial ratio of the mobile phase changes by ±10%, and the method has good durability.
[0069] Example 4
[0070] The other conditions were the same as in Example 1, and the flow rates were 0.6 ml / min, 0.8 ml / min, and 1.0 ml / min, respectively. Figure 9-10 As shown, with the change of flow rate, the retention time of 2-mercaptobenzothiazole in the system suitability derivatization solution is moderate, the separation, recovery rate and sensitivity all meet the detection requirements, the flow rate changes by ±0.2ml / min, and the method has good durability.
[0071] Example 5
[0072] The other conditions were the same as in Example 1, and the column temperatures were 35°C, 40°C, and 45°C, respectively. Figure 11-12 As shown, with the change of flow rate, the retention time of 2-mercaptobenzothiazole in the system suitability derivatization solution is moderate, the separation, recovery rate and sensitivity all meet the detection requirements, the flow rate changes by ±5°C, and the method has good durability.
[0073] Example 6
[0074] The other conditions were the same as in Example 1, and the derivatization reaction temperatures were room temperature, 40°C, 45°C, 50°C, 60°C, and 80°C, respectively. Figure 13-14The results showed that the optimal derivatization reaction temperature was 45°C. Under this condition, the recovery rate and sensitivity of 2-mercaptobenzothiazole in the derivatization solution of the system suitability met the detection requirements. The derivatization reaction was incomplete at room temperature, and the peaks of 2-mercaptobenzothiazole and dibenzothiazole disulfide existed in the derivatization solution at a wavelength of 272nm.
[0075] Example 7
[0076] The other conditions were the same as in Example 1, and the reaction times were 0 h, 0.5 h, 1 h, 3 h, and 6 h, respectively. Fig.15 As shown, with the increase of different derivatization reaction temperatures, the peak response tends to increase, and the minimum derivatization reaction time is 0.5h. Under this condition, the recovery rate and sensitivity of 2-mercaptobenzothiazole in the system suitability derivatization solution meet the detection requirements.
[0077] Comparative Example 1
[0078] The difference between this comparative example and Example 1 is that no derivatization reagent glutathione is used, and the rest is the same as Example 1. Figure 16-23 .
[0079] In Comparative Example 1, the UV absorption spectra of the dibenzothiazole disulfide reference solution and the 2-mercaptobenzothiazole reference solution show that the maximum UV absorption wavelength of dibenzothiazole disulfide is 272 nm, and the maximum UV absorption wavelength of 2-mercaptobenzothiazole is 318 nm, and the UV response difference between the two is large; the chromatograms of the 2-mercaptobenzothiazole reference solution and the dibenzothiazole disulfide reference solution both detect the 2-mercaptobenzothiazole peak and the dibenzothiazole disulfide peak. Peak, and according to the peak position, the acetonitrile ratio is 30% when 2-mercaptobenzothiazole peaks, and the acetonitrile ratio is 90% when dibenzothiazole disulfide peaks. The retention difference between the two on the C18 column is large, and the analysis time is long; only 2-mercaptobenzothiazole is detected in the 318nm chromatogram of the test solution, and only dibenzothiazole disulfide is detected at 272nm. The residual 2-mercaptobenzothiazole and dibenzothiazole disulfide cannot be detected at the same wavelength. The derivative determination method of the embodiment is better than the direct determination method of comparative example 1, and the determination is more accurate.
[0080] Comparative Example 2
[0081] The difference between this comparative example and Example 1 is that the temperature of the derivatization reaction is different, that is, the reaction is carried out at room temperature (25°C). The rest is the same as Example 1. The test results are shown in FIG. Figure 24-25 .
[0082] In Comparative Example 2, the 2-mercaptobenzothiazole reference derivatization solution, the dibenzothiazole disulfide reference derivatization solution, and the test sample derivatization solution all showed peaks of 2-mercaptobenzothiazole and dibenzothiazole disulfide at a wavelength of 272 nm, indicating that the derivatization conditions of the room temperature derivatization reaction for 0.5 h were too mild to completely convert dibenzothiazole disulfide into 2-mercaptobenzothiazole.
[0083] The derivatization conditions of the embodiment are better than those of the comparative example 2, and the reaction is more thorough.
[0084] Comparative Example 3
[0085] The difference between this comparative example and Example 1 is that the mobile phase is different in type, i.e., a non-volatile phosphate buffer solution. The rest is the same as Example 1. The test results are shown in FIG. Figure 26-27 .
[0086] In Comparative Example 3, the separation degree between 2-mercaptobenzothiazole and adjacent peaks in the system suitability solution was 3.89, and the signal-to-noise ratio of 2-mercaptobenzothiazole in the sensitivity solution was 13.96.
[0087] The mobile phase of the embodiment is superior to the mobile phase of comparative example 3 and has higher selectivity and sensitivity.
[0088] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for detecting genotoxic impurities 2-mercaptobenzothiazole and dibenzothiazole disulfide, characterized in that: The detection method adopts high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography include: using 0.05-0.2% formic acid aqueous solution as mobile phase A, using acetonitrile as mobile phase B, and the gradient elution conditions are: 0 min, mobile phase A: 65-75%, mobile phase B: 25-35%; 20min, mobile phase A: 65-75%, mobile phase B: 25-35%.
2. The detection method according to claim 1, characterized in that: The detection wavelength in the chromatographic conditions is 319 nm, and the chromatographic column uses octadecylsilane bonded silica gel as a filler.
3. The detection method according to claim 1, characterized in that: The chromatographic column is YMC-PackC18, and the size of the chromatographic column is 4.6x150mm, 3μm.
4. The detection method according to claim 1, characterized in that: The flow rate of the mobile phase in the chromatographic conditions is 0.6-1.0 mL / min, and the column temperature is 35-45°C.
5. The detection method according to claim 1, characterized in that: The detection method further comprises: (1) Preparation of the test sample derivatization solution: dilute the antibiotic sample with glutathione solution and perform a derivatization reaction; (2) Preparation of reference substance derivatization solution: The reference substance is dissolved in dimethyl sulfoxide to prepare a 0.5 mg / mL solution. The solution is diluted with solvent to prepare a stock solution. The stock solution is diluted with glutathione solution and the derivatization reaction is performed.
6. The detection method according to claim 5, characterized in that: The temperature of the derivatization reaction in steps (1) and (2) is 40-50°C.
7. The detection method according to claim 5, characterized in that: The derivatization reaction time in steps (1) and (2) is 0.5-6h.
8. The detection method according to claim 5, characterized in that: The preparation of the glutathione solution in steps (1) and (2) comprises dissolving glutathione in water and diluting it with ethanol.
9. The detection method according to claim 5, characterized in that: The reference substances in step (2) are 2-mercaptobenzothiazole and dibenzothiazole disulfide.
10. The detection method according to claim 5, characterized in that: The solvent in step (2) is 20-40% methanol solution.
